Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Research & Development (2019 - 2025)

Historic Research & Development for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $348000.0.

  • Cyclerion Therapeutics' Research & Development rose 32962.96% to $348000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $496000.0, marking a year-over-year increase of 9527.56%. This contributed to the annual value of $286000.0 for FY2024, which is 8112.21% down from last year.
  • Per Cyclerion Therapeutics' latest filing, its Research & Development stood at $348000.0 for Q3 2025, which was up 32962.96% from $56000.0 recorded in Q2 2025.
  • In the past 5 years, Cyclerion Therapeutics' Research & Development ranged from a high of $12.1 million in Q2 2021 and a low of $24000.0 during Q4 2023
  • In the last 5 years, Cyclerion Therapeutics' Research & Development had a median value of $886000.0 in 2023 and averaged $3.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 9883.38% in 2024, then surged by 32962.96% in 2025.
  • Cyclerion Therapeutics' Research & Development (Quarter) stood at $10.5 million in 2021, then plummeted by 88.76% to $1.2 million in 2022, then tumbled by 97.96% to $24000.0 in 2023, then surged by 133.33% to $56000.0 in 2024, then skyrocketed by 521.43% to $348000.0 in 2025.
  • Its Research & Development was $348000.0 in Q3 2025, compared to $56000.0 in Q2 2025 and $36000.0 in Q1 2025.